BioSpace News Archive

Congress made welcomed legislative attempts in the past to increase medical discovery such as enacting the Orphan Drug and Translational Research Acts, but they are very limited in scope; and the same holds true with, due to the COVID-19 pandemic, the Administration’s new rules regarding relaxation of regulations to enter clinical trials in national emergency situations.

Voltron Therapeutics, Inc. announced today that it has selected the peptides required to complete the structure of HaloVax for development and progression into pre-clinical animal testing of the HaloVax Self-Assembling Vaccine (SAV).

Axovant Gene Therapies Ltd. a clinical-stage company developing innovative gene therapies for neurological diseases, today announced that it had prepaid in full its $15.7 million outstanding loan from Hercules Capital, Inc. together with interest, fees and other amounts due. Following the prepayment, the credit facility and loan agreement with Hercules Capital, Inc. was terminated, and all obligations, liens and security inter

Chiesi Global Rare Diseases, a business unit of Chiesi Farmaceutici S.p.A. focused on research and development of treatments for rare and ultra-rare disorders, today announced its support for Fabry Disease Awareness Month and highlighted the company’s continued commitment to patients, caregivers and families impacted by this debilitating rare disease

CVS Health Corporation announced that, by order of its Board of Directors, its 2020 Annual Meeting of Stockholders will now be held solely by remote communication.

Incyte (Nasdaq:INCY) announces the appointment of Christine Lennon as the General Manager for Incyte Biosciences Canada, expanding the Company’s North American footprint. In her role, Christine will be responsible for the development of Incyte’s medical, regulatory and commercial strategy in Canada. “We are very pleased that Christine has joined Incyte as we expand our business in North America and establish a commercial